New Spastin mutation discovered

Posted - June 2014 in Research Highlights

Found to affect a neighbouring gene

A newly discovered spastin deletion mutation has been found to affect a neighbouring gene in ways that suggest this influences the profile of symptoms in people with this mutation.

 

BACKGROUND:

The hereditary spastic paraplegias (HSPs) are pleiomorphic disorders of motor pathway and a large number of affected genes have been discovered. Yet, mutations in SPG4/SPAST represent the most frequent molecular etiology in autosomal dominant (AD) patients and sporadic cases. We describe a large, AD-HSP Sardinian family where 5 out of several living members harbored a novel deletion affecting also the 5’UTR of SPAST and resulting in reduced expression of DPY30, the gene located upstream SPAST in a head-to-head manner.

CASE PRESENTATION:

A 54-year-old woman manifested leg stiffness at age 39 and required a cane to walk at age 50. Neurological examination disclosed mild spasticity and weakness in the legs, hyperreflexia in all limbs, and bilateral Babinski sign. She also complained of urinary urgency, but no additional neurological symptoms or signs were detected at examination.

The clinical examination of 24 additional relatives disclosed three further affected individuals, two men and one woman. In the four symptomatic patients the initial manifestations were walking abnormalities and leg stiffness with a mean age at onset (SD) of 46.75 (5.44) years (range 39-51). The mean disease duration was 13.2 (13.4) years (range 6-35), and it correlated well with clinical severity (SPRS score) (r = 0.975, p = 0.005). One patient was confined to bed and displayed knee and ankle contractures, another case needed a cane to walk, and two individuals were able to walk without aids. Interestingly, a patient had also had a miscarriage during her first pregnancy.

Gene testing revealed an heterozygous deletion spanning from the 5′-UTR to intron 4 of SPAST in the affected individuals and in one clinically unaffected woman. In three affected patients, the deletion also determined low mRNA levels of SPAST and DPY30, a component of the Set1-like multiprotein histone methyltransferase complex located upstream, head-to-head with SPAST.

CONCLUSION:

Together with data described in a Japanese family, our findings seem to suggest that genes close to spastin might be candidates in modulating the clinical phenotype. This report endorses future research on the role of neighboring genes as potential players in SPG4 disease variability.

 

SOURCE: BMC Med Genet. 2014 Apr 1;15:39. doi: 10.1186/1471-2350-15-39. PMID: 24690193  [PubMed – indexed for MEDLINE]  PMCID:  PMC3974227

Novel SPAST deletion and reduced DPY30 expression in a Spastic Paraplegia type 4 kindred.

Racis LStorti EPugliatti MAgnetti VTessa ASantorelli FM1.

1IRCCS Stella Maris, via dei Giacinti 2, 56028 Pisa, Italy.

 

Add your comment on this story